GSK-3844766A

概览

GSK-3844766A is an adjuvanted respiratory syncytial virus vaccine in older adults.

作用机制

Respiratory tract infections caused by RSV can be severe in high-risk populations, such as infants and elderly patients. Immunization remains one of the key preventative measures against RSV infection. GSK-3844766A is an adjuvanted vaccine consisting of an antigen (RSVPreF3), which induces a CD4 T cell response against RSV glycoprotein F stabilized in pre-fusion conformation, and the AS01E adjuvant, which stabilizes the antigen.

适应症

GSK-3844766A is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older by the FDA and Health Canada. In the US, it is also indicated for the active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

• Lower Respiratory Tract Disease caused by Respiratory Syncytial Virus (RSV)
• Lower Respiratory Tract Infection (LRTI)
• Severe Lower Respiratory Tract Disease caused by Respiratory Syncytial Virus (RSV)